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The magnitude, quality, and maintenance of immunological memory after infection or vaccination must be con-
sidered for future design of effective influenza vaccines. In 2009, the influenza pandemic produced disease that 
ranged from mild to severe, even fatal, illness in infected healthy adults and led to vaccination of a portion of the 
population with the adjuvanted, inactivated influenza A(H1N1)pdm09 vaccine. Here, we have proposed a multi-
parameter quantitative and qualitative approach to comparing adaptive immune memory to influenza 1 year after 
mild or severe infection or vaccination. One year after antigen encounter, severely ill subjects maintained high 
levels of humoral and polyfunctional effector/memory CD4+ T cells responses, while mildly ill and vaccinated sub-
jects retained strong cellular immunity, as indicated by high levels of mucosal homing and degranulation markers 
on IFN-γ+ antigen-specific T cells. A principal component analysis distinguished 3 distinct clusters of individuals. 
The first group comprised vaccinated and mildly ill subjects, while clusters 2 and 3 included mainly infected indi-
viduals. Each cluster had immune memory profiles that differed in magnitude and quality. These data provide 
evidence that there are substantial similarities between the antiinfluenza response that mildly ill and vaccinated 
individuals develop and that this immune memory signature is different from that seen in severely ill individuals.
Introduction
Influenza A infection is still a major infectious disease that has 
appreciable morbidity and mortality during the annual seasonal 
epidemic as during the 2009 pandemic (1). Genetic mutations are 
typically responsible for seasonal influenza outbreaks (2), and the 
emergence of an influenza pandemic results from genetic reas-
sortment among different strains and subtypes (3). Ab responses 
acquired after natural infection or seasonal vaccination do not con-
fer long-time protection against all strains because of the high sea-
sonal-virus variability (4). In addition, cellular immunity recognizes 
conserved regions of influenza proteins (5, 6) and is reported to play 
a role in reducing morbidity from influenza infection (7). Here, we 
examined and compared the level of persistence of antibody and cel-
lular memory responses both to influenza A(H1N1)pdm09 vaccina-
tion and to pandemic infection, either mild or severe.
Pandemic influenza viruses often cause severe disease in young or 
middle-aged adults, even those without preexisting comorbidities 
(8–10). The mechanism of illness associated with severe disease 
in this age group is not well understood (11), but might involve 
impaired immune responses. Serum Abs that crossreact with, but do 
not protect against, influenza A(H1N1)pdm09 virus can be found 
in middle-aged but not in young adults. These nonprotective Abs 
have been shown to induce immune complex–mediated disease after 
infection (12). High titers of serum Abs of low avidity for H1-2009 
antigen in severely ill individuals have often been associated with 
mortality (12). To et al., however, have proposed that nonneutraliz-
ing Abs with high avidity might also be associated with severe illness 
during influenza A(H1N1)pdm09 infection (13, 14). Individuals who 
survive are thus those who mounted an immune response.
The magnitude and functional characteristics of immune mem-
ory involving both Ab and T cell responses are key parameters of 
protection against future infections. As reported by Hobson et al. 
in 1972 (15), neutralizing Ab response is the reference criterion 
for evaluating the efficacy of influenza immunity for potential 
protection after vaccination. Other aspects of immunity are also 
relevant, however, such as serum avidity and T cell responses, and 
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their polyfunctionality has been associated with protection (16, 
17). Indeed, influenza-specific T cells play a crucial role in the 
control of viral influenza infection and are capable of producing 
cytokines and killing infected cells (7, 18). Still other aspects to 
be considered are postinfection mucosal and cell trafficking (19).
The mechanisms that induce these characteristics depend 
on 2 parameters that differ substantially according to whether 
vaccination or infection-induced immunization has occurred: 
antigen dose and duration of exposure. In the absence of circu-
lating antigen, immune memory is considered to have reached 
a resting state a year after the first encounter (20). It is not yet 
clear whether vaccination generates levels and characteristics of 
immune memory similar to those induced by infection itself, 
although adjuvants to vaccines are supposed to enhance both 
the signal strength and exposure duration. We recently proposed 
that the extreme heterogeneity of immune responses to influ-
enza A(H1N1)pmd09 three weeks after vaccination is related to 
individual factors, including the magnitude and quality of influ-
enza-specific immune responses before vaccination (21).
We thus examined the immunologic status of cellular and 
humoral memory of influenza A(H1N1)pdm09 to define and com-
pare the immune memory signature of severe and mild infection 
and of adjuvanted vaccination. We explored the plexus of immune 
parameters that might be used as markers of protection against 
influenza viruses. We found some significant similarities between 
mildly ill and vaccinated subjects, who shared an immune memory 
signature different from the two seen in severely ill individuals.
Results
The intensity of effector/memory humoral and cellular immune responses 
distinguishes individuals who had severe influenza A(H1N1)pdm09 infec-
tions from mildly ill or vaccinated subjects 1 year later. One year after 
influenza A(H1N1)pdm09 vaccination or infection, we stud-
ied immunologic memory parameters reported to play a role in 
either protection against influenza A(H1N1)pdm09 infection or 
its severity. These parameters included hemagglutinin inhibition 
(HI) titers (Figure 1A), serum Ab avidity (Figure 1B), counts of 
A(H1N1)pdm09 virus–specific IFN-γ/IL-2/TNF-α–secreting CD4+ 
and CD8+ T cells (Figure 1, C and D, respectively), degranulation 
capacity with A(H1N1)pdm09-specific CD107a+CD4+ and CD8+ 
T cells (Figure 1, E and F, respectively), and lung/mucosa-associ-
ated homing markers: CD49a+CD49d+CD4+ effector T cells (Fig-
ure 1G) and CD49a+CD49d+ CD8+ effector T cells (Figure 1H and 
ref. 19). Figure 1I is a radar chart summarizing adaptive memory 
immunity 1 year after infection or vaccination.
We found that the intensity of humoral responses (HI titers) 
as well as of A(H1N1)pdm09-specific cytokine-secreting CD4+ 
effector/memory T cells was significantly higher at 1 year after a 
severe A(H1N1)pdm09 infection than after vaccination; a similar 
trend existed when we compared severe to mild infection (HI titers: 
severe compared with vaccination: P = 0.0474 and compared with 
mild: P = 0.0544; CD4+ T cells: severe compared with vaccination: 
P = 0.0272 and compared with mild: P = 0.0038). On the other 
hand, the intensity of the cellular response, including IFN-γ+ CD4+ 
or CD8+ T cells bearing mucosa homing markers (CD49a and 
CD49d), was greater in mildly infected or vaccinated subjects than 
those severely ill a year earlier (P < 0.05). Expression of the degran-
ulation marker (CD107a) on effector/memory CD4+ and CD8+ 
T cells was also significantly more intense during the memory 
phase after vaccination, reflecting cellular response with cytotoxic 
potential (P < 0.01). It should be noted that serum avidity and the 
frequency of cytokine-producing CD8+ T cells specific for influ-
enza A(H1N1)pdm09 remained similar in all groups.
These results show distinct imprinting by infection and vaccina-
tion at 1 year after severe and mild infection and vaccination. To sum-
marize these similarities and disparities, we examined the intensity of 
8 parameters among the groups. In individuals with mild infection 
compared with vaccinated subjects, the intensity of 6/8 parameters 
was similar (HI titers, serum avidity, mucosa-homing effector CD4+ 
and CD8+ T cells, and cytokine-secreting effector/memory CD4+ and 
CD8+ T cells); in those with severe and mild infections, the intensity 
of 5/8 was similar (HI titers, serum avidity, cytokine-secreting CD8+ 
T cells and CD107a expression on effector/memory CD4+ and CD8+ 
T cells); and in those with severe infection and those vaccinated, 
the intensity of only 2/8 was similar (serum avidity and effector/
memory CD8+ T cells). Overall, the immune memory signature of 
severely ill individuals tended toward a high level of HI titers and 
cytokine-producing effector/memory CD4+ T cells, whereas mildly 
ill and vaccinated subjects, despite significant HI titers, had higher 
levels of mucosa-homing T cells and CD107a+ T cells in the blood at 
the memory phase than the severely ill subjects.
Distinct combinations of polyfunctionality of CD4+ and CD8+ T cells 
determine memory responses for individuals who had severe influenza 
infections, but these were strongly similar for mildly ill and vaccinated 
subjects. One hallmark of the efficacy of T cell responses against 
viral infection is the production of multiple cytokines by CD4+ 
and CD8+ cells. Figure 1, C and D, presents data according to 
the total frequency of triple-positive (TP) (IFN-γ+IL-2+TNF-α+), 
double-positive (DP) (IFN-γ+IL-2+TNF-α–, IFN-γ+IL-2–TNF-α+ or 
IFN-γ–IL-2+TNF-α+), and single-positive (SP) (IFN-γ+IL-2–TNF-α–, 
IFN-γ–IL-2+TNF-α– or IFN-γ–IL-2–TNF-α+) cytokine-secreting 
T cells. Figure 2, A and C, depict the percentages of A(H1N1)
pdm09-specific TP, DP, and SP cytokine-secreting CD4+ and 
CD8+ T cells found 1 year after severe or mild infection or vac-
cination. The results are summarized in separate radar charts for 
CD4+ and CD8+ T cells (Figure 2, B and D).
In total A(H1N1)pdm09-specific memory CD4+ T cells, severe 
influenza infection induced higher amplification of SP, DP, and 
TP cytokine-secreting memory CD4+ cells, but only the TP, IFN-γ– 
IL-2+TNF-α+ and IFN-γ–IL-2–TNF-α+ subpopulations differed 
significantly between severe and mild ill or vaccinated subjects 
(P < 0.01; Figure 2, A and B). No differences were observed when 
comparing vaccination to mild infection except for SP IFN-γ+IL-2– 
TNF-α––producing CD4+ T cells, which were more numerous at 
the memory phase after vaccination (P = 0.0134; Figure 2, A and B).
The CD8+ cytokine profile, however, did not differ significantly 
among groups (Figure 2, C and D); although the proportion of 
most cytokine-producing effector/memory CD8+ T cells tended 
to be higher after severe infection, the difference was statistically 
insignificant. Some discrepancies were observed between memory 
responses after mild infection compared with vaccination; in the 
former, we found a higher percentage of IFN-γ+IL-2–TNF-α– and in 
the latter, a higher percentage of IFN-γ–IL-2–TNF-α+.
Principal component analyses revealed distinct clusters of individuals 
with similar immune memory signatures 1 year after the A(H1N1)pdm09 
antigen encounter. To extract all the relevant information about all 
of the immune parameters amplified after vaccination or by severe 
or mild A(H1N1)pdm09 virus infection, we used a principal com-
ponent analysis (PCA). This technique is an unsupervised visual-
ization tool used to optimize our understanding of the underlying 
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structure of a data set (22). It enabled us to conduct an integrative 
analysis of the trends in the 8 immune parameters discussed above 
(HI titers, serum avidity, cytokine-producing CD4+ and CD8+ 
T cells, CD107a+ T cells, and homing markers of effector T cells) 
after normalization. Figure 3A presents the PCA. It clustered the 
57 subjects for whom we had data for all 8 immune parameters 
into 3 sets that differed significantly. The first 3 components 
explain up to 83.28% of the variance.
Figure 1
Differential intensity of long-term immune response between vaccinated and infected subjects. A box-and-whiskers plot with the 10th to 
90th percentiles is presented for each parameter. One year after the antigen encounter, we evaluated influenza-specific immune responses: 
(A) hemagglutination inhibition titers (HI titers) (HI titers ≥ 1/40: vaccination: 26/48 [54.17%]; mild: 23/48 [47.92%]; severe: 10/13 [76.92%]) and 
(B) serum avidity assay in 48 vaccinated subjects (white), 48 mildly ill subjects (orange), and 13 severely ill subjects (blue). The graph’s y axis is 
in log10 scale. (C and D) Influenza A(H1N1)pdm09 virus–specific CD4+ and CD8+ T cells were measured by secreted cytokines (Boolean gates 
for IFN-γ, IL-2, and/or TNF-α) in 30 vaccinated, 32 mildly ill, and 13 severely ill subjects. The graph’s y axis is in log10 scale. (E and F) Expres-
sion of influenza A(H1N1)pdm09 virus–specific CD107a on CD4+ and CD8+ T cells was evaluated in samples from 30 vaccinated, 32 mildly 
ill, and 13 severely ill subjects; (G and H) double CD49a- and CD49d-positive markers were evaluated on IFN-γ+CD4+ (G) and IFN-γ+CD8+ 
(H) T cells in samples from 20 vaccinated, 26 mildly ill, and 11 severely ill subjects. Statistical analyses were performed with the Mann Whitney 
U test; statistical significance is indicated. *P < 0.05; **P < 0.01. (I) Radar charts compare influenza virus–specific immune compartments of 
vaccinated (black), mildly ill (orange) and severely ill (blue) groups. The values on the axis represent the mean of each parameter derived from 
the upper and lower 95% CIs of the mean of each assay for all tested subjects. vac, vaccinated volunteers, mild, patients with mild to moderate 
A(H1N1)pdm09 pandemic virus influenza infection; severe, patients with severe A(H1N1)pdm09 pandemic virus influenza infection.
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The first cluster (cluster 1, n = 24) contained mildly ill subjects 
(n = 11; 46%) and vaccinated subjects (n = 13; 54%); it underlines 
the similarities in the memory responses after vaccination and 
infection, as shown in Figure 3B. These results further confirm 
that the subjects who were mildly ill have memory responses simi-
lar to those of vaccinated subjects.
Cluster 2, which was much smaller (n = 8), and cluster 3, which 
included 25 subjects, both comprised mainly infected individuals 
(Figure 3B), but they had 2 clearly different immune memory pro-
files. Cluster 2 included subjects with a lower intensity of immune 
memory but in which all immune functions were nonetheless rep-
resented. Cluster 3, on the other hand, included subjects with aver-
age HI titers and homing T cells (CD49a+CD49d+). These results 
further underline some similarities at the memory phase between 
severely and mildly ill individuals.
Discussion
This work is the first study, to our knowledge, to propose an 
immune signature of the immunologic memory of an influenza 
A(H1N1) virus based on 8 parameters of immunity, including 
humoral and cellular immune responses, in subjects at 1 year 
after A(H1N1)pdm09 vaccination or infection (severe or mild). At 
this memory phase, severely ill individuals could be distinguished 
by a significantly higher level of HI titers and CD4+ T cell poly-
functionality compared with mildly ill individuals and vaccinated 
individuals, whose results for these parameters could barely be 
told apart a year later.
As the world faced a new influenza pandemic in 2009, research 
focused on the persistence of neutralizing Abs against influenza 
strains that were genetically close to the influenza A(H1N1)pdm09 
strain, as imprinted during previous antigen encounters. The 
oldest cohort showed evidence of robust immunity to influenza 
A(H1N1)pdm09 with significant neutralizing capacities (23): sub-
jects born before 1930 were probably exposed to 1918-like H1N1 
and thus had high Ab titers (23, 24). In 2009, Wagar et al. stud-
ied the humoral and cellular immune memory response in a few 
individuals who were infected and/or vaccinated (25). It should be 
noted that even though the serum Ab response to influenza infec-
Figure 2
Polyfunctional influenza memory T cell responses were amplified after severe infection. Detailed analyses of SP, DP, and TP cytokine-producing 
A(H1N1)pdm09 virus–specific CD4+ T cell responses (A and B) and CD8+ T cell responses (C and D) are shown on the x axes for the vaccinated 
group (n = 30; white), the mildly ill group (n = 32; orange), and the severely ill group (n = 13; blue). The graphs’ y axes is in log10 scale. The means 
of each cytokine combination for each group are presented in black. Statistical analyses used the Mann-Whitney U test and statistical significance 
is indicated. **P < 0.01. (B and D) Radar charts present the upper and lower 95% CIs of the mean of each cytokine combination, as indicated in 
linear scale, for vaccinated (black), mildly ill (orange) and severely ill subjects (blue).
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tion or vaccination was found to be ephemeral, this study failed 
to take initial disease severity into account in assessing the persis-
tence of immune memory.
Our work, we believe, is unique in its comparison of the immune 
memory signature in individuals after vaccination, mild illness, 
and severe illness. Most of the parameters tested have been consid-
ered to be correlates or cocorrelates of protection against influen-
za viruses. Thus, the strength of our finding is that we considered 
numerous parameters in the persistence of correlates of protection 
after vaccination and infection. Recent additions to the literature 
offer relevant evidence about immune cell responses and influenza 
illness. Sridhar et al. (26) established that the high frequencies of 
IFN-γ+IL2– CD8+ cells and lung-homing and cytotoxic potential 
are strongly correlated with less severe illness. They proposed that, 
in the absence of crossreactive neutralizing Abs, these protective 
immune correlates might be used as “a guide for universal influ-
enza vaccine development.” This is consistent with our findings; 
both homing and the cytotoxic potential of CD8+ memory cells are 
features of both past vaccination and mild infection.
In addition, Wilkinson et al. (27) conducted an influenza infec-
tion study in healthy volunteers with no detectable Abs to the chal-
lenge viruses, H3N2 or H1N1. They showed that preexisting CD4+ 
T cells (with evidence of cytotoxic activity), but not CD8+ T cells, 
were associated with low virus shedding and less severe illness.
Figure 3
Differential and similar mobiliza-
tion of immune responses 1 year 
after A(H1N1)pdm09 vaccina-
tion or infection. (A) PCA of the 
immune responses showed that 
the 57 subjects with complete 
data could be segregated on the 
basis of log10 influenza A(H1N1)
pdm09–specific responses into 3 
clusters: cluster 1 (n = 24; blue), 
cluster 2 (n = 8; red), and clus-
ter 3 (n = 25; green). (B) The 
percentages of vaccinated sub-
jects (white), mildly ill subjects 
(orange), and severely ill sub-
jects (blue) for each cluster are 
summarized in the pie charts. 
(C) The radar chart presents the 
upper and lower 95% CIs of the 
means of each assay as indi-
cated in linear scale, for cluster 1 
(blue), cluster 2 (red), and clus-
ter 3 (green). Statistical analyses 
used the Mann-Whitney U test, 
and statistical significance is indi-
cated. **P < 0.01, ***P < 0.001, 
****P < 0.0001.
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Our work compares 3 groups of individuals who first encoun-
tered this antigen in 3 different sets of circumstances: individu-
als who received an adjuvanted influenza vaccine, those who had 
mild infections, and those with severe infections. A year after this 
first antigen encounter, their immune memories are considered 
to have regained the resting state. However, this memory’s persis-
tence, nature, and intensity depend on the context of the antigenic 
stimulation (antigen dose, inflammatory reaction, and durability 
of antigenic exposure) (20, 28). One may question whether antivi-
ral treatment decreased antigenic stimulation through its impact 
on viral shedding. All subjects except 1 with severe influenza 
received antiviral treatment at a median of 7 days (range: 3–11 
days) after the onset of symptoms and thus were surely exposed 
to a high antigen dose before first treatment intake. In mild infec-
tion, viral shedding peaks on average 2 days after infection, that 
is, fewer than 3 hours after symptoms start (29). Given that the 
treatment is usually first administered between 12 and 48 hours 
after the onset of symptoms, here again, total viral shedding was 
at most only slightly modified by antiviral treatment. Thus, it is 
unlikely that antiviral treatments would affect the immune out-
comes in these conditions.
At 1 year after pandemic, the serum Ab levels (geometric mean 
HI titers: 95) were considered seroprotective in 76% of those who 
were severely ill compared with those (geometric mean HI titers: 
50) in 50% of the mildly ill individuals and 56% of those who were 
vaccinated. We also found high frequencies of polyfunctional 
antigen-specific CD4+ T cells producing multiple cytokines at 
1 year after severe infections and lower frequencies after a mild 
infection or vaccination; these subjects had predominantly IFN-γ+– 
producing CD4+ T cells. We also found that the number of influen-
za A(H1N1)pdm09-specific T cells expressing degranulation mark-
ers (CD107a) in vaccinated individuals was highly variable, but that 
this population was not found at the memory phase in infected 
individuals. Of note, mouse CD4+ effectors confer protection from 
lethal influenza through perforin-mediated cytotoxicity (30).
Because infection and vaccination are different routes of immu-
nization that can dictate antigen imprinting and T cell homing 
(31–33), we also tested a mucosa-homing marker on T cells (19). A 
high level of both antigen-specific CD4+ and CD8+ T cells express-
ing CD49a+CD49d+ markers was observed in both mildly ill and 
vaccinated individuals a year after immunization, while the level 
was low in those who had had severe infections. One limitation of 
our study is that our overall picture of immunologic memory is 
that of the blood; it does not reflect tissue-associated immunity 
(upper airways). The low levels of mucosa-homing T cells at 1 year 
after severe infection might also reflect the sequestration (34) or 
exhaustion of these cells in the lungs during the initial infection.
In our quest for memory signatures of severe and mild infec-
tions and vaccination, we performed a PCA. The PCA enabled us 
to take the similarities between subjects into account to optimize 
the robustness of our information while preserving a portion of 
the variation of the initial data set. Interestingly, we found 3 clus-
ters of subjects: the first cluster consisted of both vaccinated and 
mildly ill subjects and was characterized by a higher intensity of 
mucosal-homing and degranulation markers on influenza-specific 
T cells. However, clusters 2 and 3 underlined some similarities 
at the memory phase between severely and mildly ill individuals. 
Our results are the first, to our knowledge, to show that the initial 
context of immunization (severe or mild infection or vaccination) 
dictates the magnitude and quality of the immunologic memory, 
producing a distinct signature of severe infection, while mildly ill 
and vaccinated subjects share a different signature. The contribu-
tion of age difference was evaluated according to these 3 clusters 
of immune profiles. Individuals in cluster 3 were the youngest; this 
cluster also included the largest number of mildly ill subjects, who 
were younger that the others in our study (data not shown).
It might be argued that preexisting immunity, which is age-
dependent, thus influenced the severity of the influenza illness. 
Unfortunately, data on preexisting immune responses are not avail-
able in our study groups: what we have is a snapshot of the immune 
memory against influenza. We recently published an analysis of 
immune responses before and after vaccination at day 21 and at 
memory phase month 4 (21). We found that the higher the baseline 
(of preexisting flu-specific immune responses) was, the lower the 
amplification of responses was at 3 weeks after immunization (Δ 
between baseline and 3 weeks for effector immune responses). We 
did find significant differences in the intensity of the cellular and 
humoral responses at the memory phase (month 4) between the 
low- and high-baseline groups; this suggest that baseline immune 
responses affect the amplitude of immune memory (21).
A global description distinguishing immune responses to vac-
cine and to infection is a cost-effective albeit laborious task. The 
difficulty arises in part from the multiplicity of phenotypes and 
functions that can be studied for each immune compartment. 
However, comparing the immune memory after vaccination and 
infection is essential for designing novel vaccination strategies.
Methods
Study design. This study included 50 vaccinated volunteers, 48 patients with 
mild to moderate A(H1N1)pdm09 pandemic virus influenza infection, 
and 13 with severe infection. Subjects had to meet the following eligibility 
criteria: age from 18 to 65 years, clinical examination and interview for 
medical history, documented history of influenza vaccination, no psycho-
logical, familial, sociological or geographic condition that might impede 
compliance with the study protocol, and written informed consent. Fur-
ther exclusion criteria were pregnancy or any acute or chronic illness or 
local or systemic immunosuppressive treatments that might interfere with 
the study protocol. Vaccinated volunteers and infected patients from sev-
eral French hospitals were enrolled in this protocol from September 16 
through November 22, 2010.
All vaccinated subjects were recruited from among hospital health care 
staff and received the A(H1N1)pdm09 adjuvanted vaccine (Pandemrix, 
GlaxoSmithKline) by the intramuscular route.
Positive RT-PCR for influenza A(H1N1)pdm09 virus during winter 2009 
verified the pandemic influenza of all infected subjects (mild and severe), 
and none received any influenza A(H1N1)pdm09 vaccination. So-called 
mildly ill patients reported an uncomplicated flu syndrome during the 
2009–2010 seasonal flu period. All were recruited from the GROG network 
or from dedicated pandemic consultation center registries. During this 
period, severely ill patients were diagnosed with acute respiratory distress 
syndrome (ARDS) (defined by the American-European Consensus Confer-
ence on ARDS) (35) caused by A(H1N1)pdm09 virus infection. All were 
recruited from the Réseau Européen de Ventilation Artificielle (REVA) reg-
istry (36). Table 1 summarizes the characteristics of all 3 groups of subjects.
At 10 to 12 months (autumn 2010) after their influenza A(H1N1)pdm09 
vaccination or infection, subjects provided blood samples for immunolog-
ic analyses. PBMCs were isolated on Ficoll gradients (Eurobio). Sera and 
cells were frozen before these analyses. The investigators performing the 
immunologic analyses were masked to participant vaccination or infection 
status and remained so until the end of the study.
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Hemagglutination inhibition assay. Serum Abs against nonadjuvanted 
A(H1N1)pdm09 influenza vaccine (Panenza; Sanofi Pasteur) were mea-
sured by a microtiter HI assay modified from Kendal et al. (37). Briefly, 
after treatment by receptor-destroying enzyme (RDE), serial 2-fold dilu-
tions of serum (from 1:10) were tested against 4 HA units of antigen, on 
human O Rh– red blood cells. The HI titers were defined as the reciprocal 
of the highest serum dilution that completely inhibited hemagglutination.
Serum avidity assay. Serum avidity of anti-HA Abs was evaluated by ELISA 
(38). Serum samples from donors were incubated with recombinant HA from 
A/California/07/2009(H1N1) influenza virus (Protein Sciences) coated 
on ELISA plates at a dilution equivalent to 2 μg/ml of HA, in the presence 
of serial dilutions of sodium thiocyanate (NaSCN) (Sigma-Aldrich). HRP-
conjugated mouse anti-human IgG (Southern Biotech) was incubated 
before revelation with o-phenylenediamine peroxidase substrate buffer. 
The reaction was stopped with 2N HCl, and optical density was read with 
a GENios microplate reader at 492 nm with Xfluor4 software. Serum avid-
ity was defined as the concentration of NaSCN required to induce a 50% 
inhibition of Ab binding.
Cell stimulation and intracellular cytokine staining (ICS). Frozen PBL were 
available for further analysis of influenza A(H1N1)pdm09 virus–specific T 
cells. Cells were infected for 1 hour at 37°C with or without (negative con-
trol) live pandemic influenza A/California/07/2009(H1N1) virus in RPMI 
1640 without FCS and washed before overnight incubation. Brefeldin A 
and monensin (Sigma-Aldrich) were added for the last 14 hours in the 
presence of CD107a-PE-Cy5 mAb (BD Biosciences). Cells were washed and 
stained with CD3-AmCyan, CD4–Pacific blue, and CD8-APC-H7, (Beck-
man Coulter) mAbs. The BD Cytofix/Cytoperm kit was used to permea-
bilize cells, in accordance with the manufacturer’s instructions, before 
staining for the following intracellular markers: IL-2–FITC, IFN-γ–Alexa 
Fluor 700, and TNF-α–PE–Cy7 mAbs (BD Biosciences). Two different Ab 
panels were used as follows: CD3-AmCyan/CD4–Pacific blue/CD8-APC-
H7/CD27-PE/CD45RA-ECD/CD107a-PE-Cy5/IL-2–FITC/IFN-γ–Alexa 
Fluor 700/TNF-α–PE–Cy7 or CD3-AmCyan/CD4–Pacific blue/CD8-APC-
H7/CCR5-FITC/CXCR3-PE-Cy7/CD49a-PE/CD49d-PE-Cy5/IFN-γ–Alexa 
Fluor 700. Flow cytometry analyses were performed with an LSRII flow 
cytometer (BD Biosciences Immunocytometry Systems). At least 1 × 106 
live events, according to forward- and side-
scatter parameters, were accumulated and 
analyzed for Boolean combination gating with 
FlowJo software (Tree Star Inc.). Background 
cytokine responses detected in negative con-
trols were subtracted from those detected in 
stimulated samples for every specific combi-
nation. The percentage of influenza A(H1N1)
pdm09 virus–specific CD4+ or CD8+ T cells 
expresses the sum of the 7 different cytokine 
combinations. Differentiation and homing 
molecule analysis were done with virus-stim-
ulated PBMCs.
Radar charts and PCA. The radar charts were 
designed with R, a free software environment 
for statistical computing and graphics (http://
www.r-project.org/). The PCA and hierarchi-
cal clustering (HCL) analysis used the data of 
influenza virus immune responses. Data for 
all 8 parameters were available for 57 subjects. 
To stratify the population and visualize the 
clusters, we used a part of the TM4 software 
suite, the Multi Experiment Viewer, MeV (39). 
log10 values were normalized with MeV 4.7.4 
software. The best division for the initial population was obtained for 
3 clusters (inflexion point of the Figure of Merit; ref. 40). To cluster the 
data, e.g., to stratify the initial population, we ran the k-means clustering 
algorithm for 3 clusters and performed HCL analysis on the items in each 
cluster thus created (41). HCL analysis was done with complete linkage and 
Pearson correlation. Each cluster was then colored separately. A PCA was 
run and used to attribute the overall variability in the data to a reduced set 
of variables, that is, the principal components. We used the first 3 princi-
pal components to map each element into a 3D viewer. This mathemati-
cal operation reduces the dimensionality of the data and is a simple non-
parametric method of extracting relevant information from a confusing/
complex data set (42, 43). This analysis also helped to define the relevant 
signatures associated with infection or vaccination at the memory phase.
Statistics. We used the Mann-Whitney test to compare quantitative 
variables across groups, Kruskal-Wallis test for quantitative variables 
and Fisher’s exact test to compare 3 qualitative variables. Nonparamet-
ric Spearman correlations were used for tests of 2 quantitative variables. 
Statistical significance was set at P < 0.05. All statistical analyses were per-
formed with SPSS statistical software 17.0, SAS 9.2 (SAS Institute Inc.), 
and Prism 5.0 or Microsoft Excel for Mac OS X was used for data handling 
and graphic representation.
Study approval. The trial was conducted in accordance with the latest 
amended version of the Declaration of Helsinki, Good Clinical Practice 
(GCP), and International Conference on Harmonisation (ICH) regulatory 
guidelines. The study protocol, its first amendment, and the informed con-
sent and patient information forms were reviewed and approved by the 
independent Ethics Committee of Pitié-Salpêtrière Hospital (Approved by 
CPP Ile de France 3 N° ID-RCB: 2010-A00631-38). Written informed con-
sent was obtained from each volunteer before study entry.
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